Publications du centre

Liste des publications

Publications du département d'ophtalmologie

Bienvenue sur la page dédiée aux publications scientifiques du département d'ophtalmologie du centre médical des Aravis. Notre équipe médicale s'investit activement dans la recherche et l'innovation afin d'améliorer constamment la prise en charge de nos patients. Nos travaux portent sur un large éventail de thématiques, notamment :

Domaines d'expertise

Les maladies de la cornée, telles que le kératocône, et les techniques chirurgicales associées (greffe de cornée, etc.).
Les pathologies rétiniennes, comme la DMLA ou le décollement de la rétine, avec une expertise particulière dans les traitements par injections intravitréennes et la chirurgie vitréo-rétinienne.
L'épidémiologie et la santé publique en ophtalmologie, en utilisant des bases de données nationales pour analyser les tendances et les facteurs de risque de différentes maladies oculaires.
L'impact des technologies numériques sur la santé oculaire, notamment l'utilisation de la télémédecine pour le dépistage de la rétinopathie diabétique.

Nous sommes fiers de partager ici nos contributions à l'avancement des connaissances en ophtalmologie. N'hésitez pas à consulter nos publications pour en savoir plus sur nos domaines d'expertise et nos recherches en cours.

Afficher tous

2024

Garcher, Catherine P Creuzot; Massin, Pascale; Srour, Mayer; Baudin, Florian; Dot, Corinne; Nghiem-Buffet, Sylvia; Girmens, Jean-Francois; Collin, Cedric; Ponthieux, Anne; Delcourt, Cecile

Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study Article de journal

Dans: Acta Ophthalmol., vol. 102, no. 4, p. e548–e556, 2024.

Résumé | BibTeX | Étiquettes: anti-VEGF; diabetic macular oedema; management; real-world; treatment

@article{Creuzot_Garcher2024-wm,

title = {Management of diabetic macular oedema in France from 2012 to 

 2018: The nationwide LANDSCAPE study},

author = {Catherine P Creuzot Garcher and Pascale Massin and Mayer Srour and Florian Baudin and Corinne Dot and Sylvia Nghiem-Buffet and Jean-Francois Girmens and Cedric Collin and Anne Ponthieux and Cecile Delcourt},

year  = {2024},

date = {2024-06-01},

journal = {Acta Ophthalmol.},

volume = {102},

number = {4},

pages = {e548–e556},

publisher = {Wiley},

abstract = {OBJECTIVE: To describe the management of diabetic macular oedema 

 (DME) patients from the entire French population between 2012 

 and 2018. METHODS: In this retrospective longitudinal study, we 

 identified adults treated for DME from the French population 

 using the exhaustive French National Health Information database 

 (SNDS), and an algorithm based on diagnosis and procedure codes, 

 and reimbursed treatments. RESULTS: Between 2012 and 2018, we 

 identified 53 584 treated DME patients, who were followed for up 

 to 7 years from DME treatment initiation. Optical coherence 

 tomography (OCT) became the predominant imaging tool to diagnose 

 DME. Only 14% of patients consulted a diabetologist or 

 endocrinologist in the 3 months prior to initiating DME 

 treatment, whereas 84% consulted a general practitioner. The 

 percentage of patients consulting an ophthalmologist declined 

 over time, from 97% of patients in Year 1 (median of 9 

 consultations), to 46% in Year 7 (median of 7 consultations). 

 The median DME treatment duration with an anti-VEGF and/or 

 dexamethasone implant treatment was 9 months; 54% of patients 

 had a treatment duration less than 1 year. First-line treatment 

 was more common with ranibizumab (55% of patients) than with 

 aflibercept (30%), or dexamethasone implant (15%). About 25% 

 of patients who initiated anti-VEGF treatment switched treatment 

 at least once, while 30% of patients who initiated 

 dexamethasone implant switched to anti-VEGF treatment at least 

 once. CONCLUSIONS: French DME patients seem well-monitored by 

 their ophthalmologist, but median DME treatment duration was 

 just 9 months. These results emphasise the challenge to manage 

 and treat patients with DME over the long term.},

keywords = {anti-VEGF; diabetic macular oedema; management; real-world;   treatment},

pubstate = {published},

tppubtype = {article}

}

Fermer

Explorer

Recherche

Garcher, Catherine P Creuzot; Massin, Pascale; Srour, Mayer; Baudin, Florian; Dot, Corinne; Nghiem-Buffet, Sylvia; Girmens, Jean-Francois; Collin, Cedric; Ponthieux, Anne; Delcourt, Cecile

Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study Article de journal

Dans: Acta Ophthalmol., vol. 102, no. 4, p. e548–e556, 2024.

Résumé | BibTeX

@article{Creuzot_Garcher2024-wm,

title = {Management of diabetic macular oedema in France from 2012 to 

 2018: The nationwide LANDSCAPE study},

author = {Catherine P Creuzot Garcher and Pascale Massin and Mayer Srour and Florian Baudin and Corinne Dot and Sylvia Nghiem-Buffet and Jean-Francois Girmens and Cedric Collin and Anne Ponthieux and Cecile Delcourt},

year  = {2024},

date = {2024-06-01},

journal = {Acta Ophthalmol.},

volume = {102},

number = {4},

pages = {e548–e556},

publisher = {Wiley},

abstract = {OBJECTIVE: To describe the management of diabetic macular oedema 

 (DME) patients from the entire French population between 2012 

 and 2018. METHODS: In this retrospective longitudinal study, we 

 identified adults treated for DME from the French population 

 using the exhaustive French National Health Information database 

 (SNDS), and an algorithm based on diagnosis and procedure codes, 

 and reimbursed treatments. RESULTS: Between 2012 and 2018, we 

 identified 53 584 treated DME patients, who were followed for up 

 to 7 years from DME treatment initiation. Optical coherence 

 tomography (OCT) became the predominant imaging tool to diagnose 

 DME. Only 14% of patients consulted a diabetologist or 

 endocrinologist in the 3 months prior to initiating DME 

 treatment, whereas 84% consulted a general practitioner. The 

 percentage of patients consulting an ophthalmologist declined 

 over time, from 97% of patients in Year 1 (median of 9 

 consultations), to 46% in Year 7 (median of 7 consultations). 

 The median DME treatment duration with an anti-VEGF and/or 

 dexamethasone implant treatment was 9 months; 54% of patients 

 had a treatment duration less than 1 year. First-line treatment 

 was more common with ranibizumab (55% of patients) than with 

 aflibercept (30%), or dexamethasone implant (15%). About 25% 

 of patients who initiated anti-VEGF treatment switched treatment 

 at least once, while 30% of patients who initiated 

 dexamethasone implant switched to anti-VEGF treatment at least 

 once. CONCLUSIONS: French DME patients seem well-monitored by 

 their ophthalmologist, but median DME treatment duration was 

 just 9 months. These results emphasise the challenge to manage 

 and treat patients with DME over the long term.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

Fermer